Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eclipse Axcis PTMR Clinical Data Could Bring Approval In September

This article was originally published in The Gray Sheet

Executive Summary

Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.

You may also be interested in...



Postmarket Surveillance Orders Expected To Follow Final Rule

The Center for Devices and Radiological Health plans to issue new orders for postmarket surveillance in several device areas soon after issuing a final rule on the Safe Medical Devices Act Sec. 522 provision.

BELIEF Data May Dispel "Placebo Effect" Shadow Over Eclipse PTMR

Results from the "Blinded Evaluation of Laser 'PTMR' Intervention Electively For angina pectoris" (BELIEF) trial may represent a key step in restoring faith in the clinical efficacy of percutaneous transmyocardial revascularization and dispelling doubts raised that the therapy has no benefits beyond a placebo effect.

Eclipse's PACIFIC Trial Suggests Improved Outcomes For PTMR Patients

Eclipse Surgical's PACIFIC trial evaluating percutaneous transmyocardial revascularization (PTMR) for refractory angina shows a significant increase in patients' exercise tolerance, but leaves open the question of whether or not they experience a placebo effect from the procedure.

Related Content

UsernamePublicRestriction

Register

MT014765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel